Study overview
| Study | Year | Design | Pts/pts with NOS* (%) | Flow diversion devices used | Dedicated NOS F/U | Comments |
| Yu et al22 | 2012 | PM | 143/14 (10.2%) | PED | NR | |
| Szikora et al28 | 2013 | PS | 29/16 (55.2%) | PED, Silk | NR | Overlap with PUFS/Sahlein et al46 |
| O’Kelly et al26 | 2013 | PM | 97/36 (37.1%) | PED | No | Data discrepancy in the manuscript, data from text were used |
| Moon et al35 | 2014 | RS | 20/19 (95%) | PED | NR | Data recalculated |
| Tanweer et al37 | 2014 | RS | 41/19 (46.3%) | PED | Yes | Data discrepancy in the manuscript, data from text were used |
| Zanaty et al34 | 2014 | RS | 157/51 (33.8%) | PED | NR | |
| Zhou et al38 | 2014 | PS | 28/11 (39.3%) | Tubridge | NR | |
| Puffer et al31 | 2014 | PM | 44/24 (54.5%) | PED, Silk, Surpass | NR | Overlap with PUFS/Sahlein et al.46. Data recalculated |
| Sahlein et al46 | 2015 | PM | 108/39 (36.1%) | PED | Yes | Only patients with initial aneurysm-induced NOS included |
| Zanaty et al45 | 2015 | RS | 44/12 (27.3%) | PED | NR | |
| Breu et al49 | 2016 | RS | 28/10 (53.7%) | Silk, PED | NR | Data recalculated |
| Kim et al53 | 2016 | RM | 45/18 (40%) | PED | NR | |
| Brown et al54 | 2016 | RM | 45/45 (100%) | PED | NR | Overlap with PUFS/Sahlein et al46 |
| Miyachi et al64 | 2017 | RM | 24/18 (75%) | PED | No | Data recalculated |
| Silva et al71 | 2018 | RS | 115/21 (18.3%) | PED | NR | |
| Oishi et al73 | 2018 | RS | 100/38 (38%) | PED | NR | |
| Yan et al79 | 2019 | RS | 126/50 (39.7%) | PED | NR | Data recalculated |
| Wang et al76 | 2019 | RS | 22/22 (100%) | PED | No | Data recalculated |
| Boulouis et al7 | 2021 | RM | 55/54† (98.2%) | PED, Silk, p64, Derivo, Surpass | No | Raw data access |
| Fujii et al93 | 2022 | RS | 112/29 (25.9%) | PED | NR | Potential overlap with Oishi et al73 |
| Xu et al95 | 2022 | RS | 189/29 (15.3%) | PED | Yes | |
| Lee et al94 | 2022 | RS | 49/28 (57.1%) | NR | NR |
*NOS=neuro-ophthalmological symptoms induced by internal carotid artery aneurysm, treated with flow diversion.
†One patient treated with parent vessel occlusion excluded from the original publication.107
F/U, follow-up; NR, not reported; PED, Pipeline embolization device; PM, prospective multicenter; PS, prospective single-center; RM, retrospective multi-center; RS, retrospective single-center.